Recombinant Human Tumor protein 63(TP63)

In Stock
Code CSB-EP887971HU
Size $1812 How to order?
Image
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names TP63
Uniprot No. Q9H3D4
Research Area Apoptosis
Alternative Names AIS; Amplified in squamous cell carcinoma ; B(p51A); B(p51B); Chronic ulcerative stomatitis protein; CUSP; DN p63 alpha 1; DNp63; EEC3; id:ibd3516; Keratinocyte transcription factor ; Keratinocyte transcription factor KET; KET; LMS; MGC115972; MGC192897; NBP; OFC8; OTTHUMP00000209732; OTTHUMP00000209733; OTTHUMP00000209734; OTTHUMP00000209735; OTTHUMP00000209737; OTTHUMP00000209738; OTTHUMP00000209739; OTTHUMP00000209740; OTTHUMP00000209741; OTTHUMP00000209742; OTTHUMP00000209743; OTTHUMP00000209744; p40; p51; P51/P63; p53-related protein p63; p53CP; p63; P63_HUMAN; p73H; p73L; RHS; SHFM4; TAp63alpha; TP53CP; TP53L; TP63; TP73L; Transformation related protein 63; Transformation-related protein 63; Trp53rp1; Trp63; Tumor protein 63; Tumor protein p53-competing protein ; Tumor protein p53-like ; Tumor protein p63; Tumor protein p63 deltaN isoform delta; Tumor protein p73; Tumor protein p73-like
Species Homo sapiens (Human)
Source E.coli
Expression Region 1-680aa
Target Protein Sequence MNFETSRCATLQYCPDPYIQRFVETPAHFSWKESYYRSTMSQSTQTNEFLSPEVFQHIWDFLEQPICSVQPIDLNFVDEPSEDGATNKIEISMDCIRMQDSDLSDPMWPQYTNLGLLNSMDQQIQNGSSSTSPYNTDHAQNSVTAPSPYAQPSSTFDALSPSPAIPSNTDYPGPHSFDVSFQQSSTAKSATWTYSTELKKLYCQIAKTCPIQIKVMTPPPQGAVIRAMPVYKKAEHVTEVVKRCPNHELSREFNEGQIAPPSHLIRVEGNSHAQYVEDPITGRQSVLVPYEPPQVGTEFTTVLYNFMCNSSCVGGMNRRPILIIVTLETRDGQVLGRRCFEARICACPGRDRKADEDSIRKQQVSDSTKNGDGTKRPFRQNTHGIQMTSIKKRRSPDDELLYLPVRGRETYEMLLKIKESLELMQYLPQHTIETYRQQQQQQHQHLLQKQTSIQSPSSYGNSSPPLNKMNSMNKLPSVSQLINPQQRNALTPTTIPDGMGANIPMMGTHMPMAGDMNGLSPTQALPPPLSMPSTSHCTPPPPYPTDCSIVSFLARLGCSSCLDYFTTQGLTTIYQIEHYSMDDLASLKIPEQFRHAIWKGILDHRQLHEFSSPSHLLRTPSSASTVSVGSSETRGERVIDAVRFTLRQTISFPPRDEWNDFNFDMDARRNKQQRIKEEGE
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 80.8kDa
Protein Length Full Length
Tag Info N-terminal 6xHis-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer Tris-based buffer,50% glycerol
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time 3-7 business days
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.
Gene References into Functions
  1. TP63 role in the squamous cancer progression.CCAT1 is a key target co-regulated by TP63 and SOX2 through a super-enhancer in squamous cancer cells. PMID: 30190462
  2. lncRNA RP185F18.6 and DeltaNp63 may be considered unfavorable biomarkers, whereas GSDMD may be a favorable biomarker in colorectal cancer (CRC) ; these markers may prove valuable in the future diagnosis and prognosis of CRC. PMID: 30226619
  3. Data identified an enhancer region within the TP63/LEPREL1 locus containing genetic variants associated with bladder cancer risk. PMID: 29956121
  4. The malignant lesions showed significantly lower values than the benign lesions in the percentage of p63+ clusters, the percentage of p63+ single cells in the clusters, and the number of p63+ single cells in the background. PMID: 30043485
  5. Expression of TAp63, IKKbeta and XBP1s is also increased in livers of obese patients with liver steatosis . PMID: 28480888
  6. p63 may act as either an oncogene or a tumor suppressor gene in different scenarios: TA isoforms of p63 gene are generally tumor-suppressive through repressing cell proliferation, survival and metastasis; DeltaN isoforms, however, may initiate tumorigenesis via promoting cell proliferation and survival. (Review) PMID: 28975366
  7. Low TP63 expression is associated with neoplasms. PMID: 29180475
  8. Studies suggest for dissecting tumor protein p63 (p63)-controlled mechanisms in normal and diseased epidermal development and for developing therapeutic options [Review]. PMID: 29103147
  9. In leukoplakia, increased expression of survivin reflects on the increased expression of ki-67 and p63. PMID: 28346726
  10. Gene-gene interaction between MSX1 and TP63 may influence the risk of nonsyndromic cleft lip with or without cleft palate in Asian populations. PMID: 29341488
  11. High N-terminally truncated isoform of p63 expression is associated with squamous cell carcinogenesis. PMID: 29735662
  12. The rs35592567 polymorphism in TP63 affected the expression of TP63 by interfering with its interaction with miR-140, and could serve as an explanation for the increased risk of Gastric Cancer. PMID: 29763931
  13. The data from this study showed that p63 was a tumor suppressor mainly through regulating PTEN in chondrosarcoma cells. PMID: 29441939
  14. we first demonstrated that upregulation of P63 in the cartilage tissues of osteoarthritis (OA) patients inhibited chondrocyte autophagy thereby contributing to the malignant progression of OA. PMID: 29442026
  15. high DeltaNp63beta expression up-regulates KLK6-PAR2 and down-regulates PAR1, inducing malignant transformation in oral epithelium with stimulating proliferation through ERK signal activation PMID: 29224812
  16. multiple ankyloblepharon-ectodermal defects-cleft lip/palate syndrome-associated p63 mutations, but not those causative of other diseases, lead to thermodynamic protein destabilization, misfolding, and aggregation PMID: 29339502
  17. LINC01503 is increased in squamous cell carcinoma (SCC) cells compared with non-tumor cells. TP63 bound to the super enhancer at the LINC01503 locus activates its transcription which promotes SCC cell proliferation, migration, invasion, and growth of xenograft tumors. PMID: 29454790
  18. we provide evidence that S100A7 also inhibits YAP expression and activity through p65/NFkappaB-mediated repression of DeltaNp63, and S100A7 represses drug-induced apoptosis via inhibition of YAP. PMID: 28923839
  19. DeltaNp63 promotes head and neck squamous cell carcinoma tumorigenesis via regulation of hyaluronic acid metabolism. p63 expression is a negative prognostic factor of HNSCC patient survival. PMID: 29162693
  20. cases illustrate that: there is significant familial variability, including discordant major but concordant minor anomalies in the first ever reported set of molecularly confirmed monozygotic twins with pathogenic variants in TP63. PMID: 29130604
  21. results reveal a critical role for KMT2D in the control of epithelial enhancers and p63 target gene expression. PMID: 29440247
  22. Loss of Nrf2 inhibits deltaNp63 stem cell mobilization, a key event for reconstitution of radiation-injured lung, while promoting a myofibroblast phenotype that is central for fibrosis. PMID: 28870520
  23. PKC-delta played as a protective role in squamous cell carcinomas partly by down-regulating p63, leading to the suppression of squamous cell carcinomas cell proliferation PMID: 28756980
  24. Immunocytochemical staining using cocktail antibody targeting p63/CK14 was useful for the differential diagnosis of FA and DCIS in FNAC of the breast. PMID: 28685877
  25. Authors conclude that TP63 mutations are frequent in cutaneous melanoma, support UV etiology, but their role in melanomagenesis is unclear. PMID: 28849221
  26. that both major p63 protein isoforms are expressed in triple-negative breast cancers with different tumour characteristics, indicating distinct functional activities of p63 variants in breast cancer PMID: 29484502
  27. p63-DBD is capable of binding to anti-apoptotic BclxL via its DNA binding interface, a feature that has only been shown for p53 so far. PMID: 27225672
  28. The data indicate that EPCR can regulate p63, is associated with highly proliferative keratinocytes, and is a potential human epidermal stem cell marker. PMID: 28480559
  29. miR-124 regulates p63 via iASPP, while p63 targets miR-155 via the modulation of STAT1 expression in colorectal cancer. PMID: 28418858
  30. The number of p63(+) cells is significantly higher in both hyperplastic (1.53-fold, P < 0.0001) and squamous metaplastic (2.02-fold, P < 0.0001) epithelium from nasal polyps than from healthy controls PMID: 27807867
  31. In p53-deficient breast cancers, compensatory mechanism of NFkB repression by p63 and p73 during genotoxic stress could lead to complex effects that would influence all aspects of tumor progression. PMID: 29107083
  32. findings illustrate that DeltaNp63alpha can inhibit the levels of LIF mRNA by direct transcription regulation and decrease LIF mRNA stability by suppressing the expression of Lnc-LIF-AS. An inverse interaction of LIF and DeltaNp63alpha expression was as well validated in clinical samples of cervical cancer, and high level of LIF in cervical cancers was related with poor patient survival. PMID: 28391028
  33. Negative staining for CK5/6 and p63 can be helpful to distinguish Well-differentiated neuroendocrine tumors (WDNETs) from cutaneous adnexal neoplasms. It is important to consider WDNETs in the differential diagnosis of cutaneous adnexal neoplasms as low-grade tumors may be the first sign of aggressive metastatic disease PMID: 28417484
  34. EGFR pathway gene expression analysis indicated that DeltaNp63 alters EGFR-regulated genes involved in cell adhesion, migration, and angiogenesis. Addition of EGF or neutralizing EGFR antibodies demonstrated that EGFR activation is responsible for DeltaNp63-mediated loss of cellular adhesion PMID: 28349272
  35. SNHG1 might play an oncogenic role in SCC through ZEB1 signaling pathway by inhibiting TAp63. PMID: 28415044
  36. This review discusses the evidence of DeltaNp63alpha as a master regulator of epithelial-mesenchymal transition (EMT) components and miRNA, highlighting the need for a deeper understanding of its role in EMT.[review] PMID: 27924063
  37. miR-223-5p overexpression is a putative pathological mechanism of tumor invasion and a promising therapeutic target; both miR-223-5p and p63 may be prognostic factors in vulvar cancer PMID: 27359057
  38. miR-133b plays an important role in the anti-tumor effects of TAp63 in colorectal cancer. PMID: 27894087
  39. Data show that a dominant-negative effect is widely spread within the p53/p63/p73 family as all p53 loss-of-function hotspot mutants and several of the isoforms of p53 and p73 tested exhibit a dominant-negative potential. PMID: 27589690
  40. As a transcriptionally regulated program, urothelial differentiation operates as a heterarchy, wherein GATA3 is able to co-operate with FOXA1 to drive expression of luminal marker genes, but that P63 has potential to transrepress expression of the same genes. PMID: 28282036
  41. the majority of cells within the tumor appears to express predominantly TAp63 isoform. While DeltaNp63 exerts its effects by regulating a PI3K/CD44v6 pathway. PMID: 27494839
  42. These data suggest that TP63 is a novel Lacrimo-auriculo-dento-digital syndrome gene and may also influence corneal thickness and risk for open-angle glaucoma. PMID: 28400699
  43. the strong repression of Np63 by H-RAS and PIK3CA and induction of EMT suggest that this process is critical for mammary tumorigenesis. PMID: 27681615
  44. Study reveals the existence of a functional cross-talk between two distinct post translational modification controlling DeltaNp63alpha protein turnover. The sumoylation and ubiquitylation of DeltaNp63alpha are strongly intertwined, and none of them can efficiently occur if the other is impaired. PMID: 29246538
  45. This study suggests that in patients with CD30+ lymphoproliferative disorders, an aggressive clinical course cannot be defined by the presence of TP63 rearrangements, as was recently shown in systemic ALK negative anaplastic large cell lymphoma. PMID: 27146432
  46. This study revealed the possible association between TP63 and Mullerian duct anomalies and suggested a potential contribution of microRNA-regulated expression of genes in the etiology of Mullerian duct anomalies. PMID: 27798044
  47. the roles of DeltaNp63alpha during corneal wound healing PMID: 29090620
  48. We identified a list of thirty genes repressed by DeltaNp63 in a SETDB1-dependent manner, whose expression is positively correlated to survival of breast cancer patients. These results suggest that p63 and SETDB1 expression, together with the repressed genes, may have diagnostic and prognostic potential PMID: 26840455
  49. Dysregulation of JAM-A via p63/GATA-3 signaling pathway occurs in squamous cell carcinomas of the head and neck. PMID: 27036044
  50. This study investigated the expression of p40 protein in meningiomas and explored its usefulness as prognostic marker in addition to PgR and Ki67. PMID: 27394131

Show More

Hide All

Involvement in disease Acro-dermato-ungual-lacrimal-tooth syndrome (ADULT syndrome); Ankyloblepharon-ectodermal defects-cleft lip/palate (AEC); Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 (EEC3); Split-hand/foot malformation 4 (SHFM4); Limb-mammary syndrome (LMS); Ectodermal dysplasia, Rapp-Hodgkin type (EDRH); Non-syndromic orofacial cleft 8 (OFC8)
Subcellular Location Nucleus.
Protein Families P53 family
Tissue Specificity Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type i
Database Links

HGNC: 15979

OMIM: 103285

KEGG: hsa:8626

STRING: 9606.ENSP00000264731

UniGene: Hs.137569

Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
Address
7505 Fannin St. Ste 610-312, Houston, TX 77054, USA
Join Us with

Subscribe newsletter

Leave a message

© 2007-2022 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1